Literature DB >> 28483968

Preanalytical Stability of Antibodies to Pathogenic Antigens.

Verity S Hodgkinson1, Sam Egger2, Fay Betsou3, Tim Waterboer4, Michael Pawlita4, Angelika Michel4, Mark S Baker5, Emily Banks6, Freddy Sitas1,7,8.   

Abstract

Background: Serologic testing for antibodies against epitopes from pathogens is a valuable tool for investigating the relationship between infection and disease. This study comprehensively evaluates the impact of preanalytic variation on antibody seropositivities to a selected set of antigens arising from delays in processing of blood samples, preprocessing storage temperature, and vacutainer type.
Methods: We assessed peripheral blood collected from 29 volunteers in four different Vacutainer types [ethylenediaminoetetraacetic acid (EDTA), acid-citrate-dextrose (ACD), lithium heparin (LH), serum separator tubes (SST)], and stored at 4°C or room temperature for 0, 1, 2, 3, 4, 5, and 6 days before processing. Multiplex serology was used to determine antibody reactivity against 35 antigens derived from human papillomaviruses, human polyomaviruses, Epstein-Barr virus, and Helicobacter pylori Cohen's κ statistic was used to measure agreement on seropositivity status between samples exposed to standard and nonstandard clinical practice conditions.
Results: For samples processed without delay, κ was not associated with storage-temperature (P value range 0.23 to 0.95) or vacutainer type (P value range, 0.35-0.89). Kappa did not significantly decline with increasing delays in processing for any vacutainer-type storage temperature combination (P slope range, 0.06-1.00).Conclusions: Antibodies to epitopes from various pathogenic infectious agents can be measured reliably from samples stored in SST, EDTA, ACD, or LH vacutainers at either room temperature or 4°C for up to 6 days before processing.Impact: Serologic testing is robust to several preanalytic options. These findings are particularly important for epidemiologic studies recruiting participants from remote settings where sample exposure to preanalytic conditions can vary considerably. Cancer Epidemiol Biomarkers Prev; 26(8); 1337-44. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28483968     DOI: 10.1158/1055-9965.EPI-17-0170

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Effects of anticoagulants and Ficoll on human serum antibody reactivities and functions against Mycobacterium tuberculosis.

Authors:  Nicholas J Gadsden; Yanyan Liu; Stephanie Gati; Tingting Chen; Elizabeth R Jenny-Avital; Jacqueline M Achkar
Journal:  Tuberculosis (Edinb)       Date:  2020-01-10       Impact factor: 3.131

2.  Kinetics of anti-SARS-COV2 spike protein IgG and IgA antibodies at 4°C: Implications for convalescent plasma stability.

Authors:  Daniele Focosi; Giovanna Moscato; Mauro Pistello; Fabrizio Maggi
Journal:  Transfus Med       Date:  2021-04-25       Impact factor: 2.019

3.  Multipanel assay of 17 tumor-associated antibodies for serological detection of stage 0/I breast cancer.

Authors:  Makoto Sumazaki; Hideaki Ogata; Yoshihiro Nabeya; Akiko Kuwajima; Takaki Hiwasa; Hideaki Shimada
Journal:  Cancer Sci       Date:  2021-03-16       Impact factor: 6.716

4.  Stability of important antibodies for kidney disease: pre-analytic methodological considerations.

Authors:  Qiuxia Han; Songyan Li; Bo Fu; Dongwei Liu; Maoqing Wu; Xiaoli Yang; Guangyan Cai; Zhangsuo Liu; Xiangmei Chen; Hanyu Zhu
Journal:  PeerJ       Date:  2018-07-09       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.